Hormonal therapy plus radiation increases survival in node-positive prostate cancer
the ONA take:
According to a new study published online in the Journal of the National Cancer Institute, researchers from the American Cancer Society and Massachusetts General Hospital Cancer Center in Boston have found that the addition of radiotherapy to hormonal therapy may improve survival in men with node-positive prostate cancer who are at significant risk of cancer-related death.
The study showed that approximately half of patients with node-positive prostate cancer in the United States who had not received combined radiation therapy and hormonal therapy and were therefore not receiving the treatment that could best inhibit tumor growth and improve survival.
"Our analysis of a large national database revealed that adding radiation therapy to androgen-deprivation therapy decreased the risk of death in these patients by 50 percent over five years," says Jason Efstathiou, MD, DPhil, of the MGH Cancer Center and Department of Radiation Oncology, senior author of the study.
Researchers found that more aggressive local management of prostate cancer that is limited to the pelvis can result in more durable disease control, limit cancer metastasis, and potentially cure some patients.
Addition of radiotherapy to hormonal therapy may improve survival in men with node-positive prostate cancer.
Sign Up for Free e-newsletters
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
- Mindfulness Training May Improve End-of-Life Conversations in Advanced Cancer
- Study Suggests Greater Focus on the Needs of Family Caregivers of Patients With Cancer
- First Antibody-Based Treatment Regimen Approved for First-Line Treatment of Multiple Myeloma
- Increased Diabetes Risk Associated With Cancer Development
- Childhood Neuroblastoma Survivors at Risk for Psych Impairment
- Drug Classification of Trastuzumab
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|